References

Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L., De La Chapelle, A., et al. (1999). Cancer risk in mutation carriers of

DNA-mismatch-repair genes. International Journal of Cancer, 81, 214–218. American Cancer Society. (2002). Cancer facts and figures 2002.

Atlanta, GA: Author. Bast, R.C., Jr., Klug, T.L., St. John, E., Jenison, E., Niloff, J.M., Lazarus, H., et al. (1993). A radioimmunoassay

using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New England Journal of Medicine, 309, 883–887. Bell, R.,

Petticrew, M., & Sheldon, T. (1998). The performance of screening tests for ovarian cancer: Results of a systematic review. British Journal

of Obstetrics and Gynaecology, 105, 1136–1147. Berchuck, A., & Evans, A.C. (1997). Tumor markers. In W.J. Hoskins, C.A. Perez, & R.C.

Young (Eds.), Principles and practice of gynecologic oncology (2nd ed., pp. 177–195). Philadelphia: Lippincott-Raven.

Junor EJ. The impact of specialist training for surgery in ovarian cancer. Int J Gynecol Cancer 2000;10(Suppl. 1):16–8. 17 McGuire WP.

CA-125 and early ovarian cancer: does this help the clinician or further muddy the water? J Clin Oncol 2005;23:5862–4. 18 Monk BJ,

DiSaia PJ. Is there a role for less than radical primary surgical management of epithelial ovarian cancer: the United States experience

and debate. Int J Gynecol Cancer 2005;15(Suppl. 3):199–205. 19 Colombo N, Parma G, Lapresa  MT, Maggi F, Piantanida P, Maggioni

A. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer  2005;15(Suppl. 3):206–211. 20

Pfisterer J, Harter P, Canzler U et al. The role of surgery in recurrent ovarian cancer. Int J Gynecol  Cancer 2005;15(Suppl. 3):195–198.

Last updated Nov 26/06